AI Engines For more Details: Perplexity Kagi Labs You
Treatment of Bacterial Infections: Sulfacetamide sodium is primarily used to treat bacterial infections of the skin, such as acne vulgaris, rosacea, and seborrheic dermatitis. It is also used in the treatment of bacterial conjunctivitis (pink eye) and other eye infections caused by susceptible organisms.
Mechanism of Action: Sulfacetamide sodium works by inhibiting the growth and reproduction of bacteria. It is a sulfonamide antibiotic that interferes with the synthesis of dihydrofolic acid, a precursor to folate, which is essential for bacterial growth. By inhibiting the enzyme dihydropteroate synthase, sulfacetamide sodium disrupts the production of folate, ultimately leading to bacterial cell death.
Topical and Ophthalmic Formulations: Sulfacetamide sodium is available in various formulations for topical application to the skin and as eye drops for ocular use. Topical formulations may be in the form of creams, lotions, gels, or cleansers, while ophthalmic formulations are typically in the form of eye drops.
Broad Spectrum of Activity: Sulfacetamide sodium has a broad spectrum of activity against both gram-positive and gram-negative bacteria, including common pathogens such as Staphylococcus aureus, Streptococcus pyogenes, Escherichia coli, and Haemophilus influenzae, among others.
Anti-inflammatory Properties: In addition to its antibacterial effects, sulfacetamide sodium may have anti-inflammatory properties that contribute to its efficacy in the treatment of inflammatory skin conditions such as acne and rosacea. It can help reduce redness, swelling, and inflammation associated with these conditions.
Adverse Effects: Common side effects of sulfacetamide sodium may include local irritation, burning, stinging, or itching at the site of application. Rare but serious adverse effects may include allergic reactions, severe skin reactions (e.g., Stevens-Johnson syndrome), or eye irritation and sensitivity with ocular use. It is essential to discontinue use and seek medical attention if any adverse reactions occur.
Pregnancy and Lactation: The safety of sulfacetamide sodium use during pregnancy and lactation has not been well established. While topical use may pose minimal risk, systemic absorption and potential effects on the fetus or breastfeeding infant should be considered. The use of sulfacetamide sodium during pregnancy and lactation should be based on a careful assessment of the benefits and risks and under the guidance of a healthcare professional.
Bacterial Resistance: As with other antibiotics, the overuse or misuse of sulfacetamide sodium can contribute to the development of bacterial resistance. It is essential to use sulfacetamide sodium judiciously and according to specific treatment guidelines to minimize the risk of resistance and ensure optimal efficacy.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | -0.3 | |
| ADHD | 0.9 | 0.3 | 2 |
| Allergic Rhinitis (Hay Fever) | 1.3 | 0.6 | 1.17 |
| Allergies | 1.8 | 1.5 | 0.2 |
| Allergy to milk products | 1.1 | 1.2 | -0.09 |
| Alopecia (Hair Loss) | 0.1 | 0.1 | |
| Alzheimer's disease | 1.9 | 2.3 | -0.21 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.7 | 0.5 | 2.4 |
| Ankylosing spondylitis | 1.7 | 0.9 | 0.89 |
| Anorexia Nervosa | 0.7 | 1 | -0.43 |
| Antiphospholipid syndrome (APS) | 0.1 | 0.1 | |
| Asthma | 1.3 | 0.8 | 0.63 |
| Atherosclerosis | 1 | 0.1 | 9 |
| Atrial fibrillation | 1.6 | 1.2 | 0.33 |
| Autism | 2.1 | 3 | -0.43 |
| Autoimmune Disease | 0.9 | 0.3 | 2 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 0.1 | 0.1 | |
| Bipolar Disorder | 1.2 | 0.6 | 1 |
| Brain Trauma | 0.3 | 0.9 | -2 |
| Breast Cancer | 0.1 | 0.1 | |
| Cancer (General) | 0.7 | -0.7 | |
| Carcinoma | 1.6 | 1 | 0.6 |
| Celiac Disease | 0.4 | 1.5 | -2.75 |
| Cerebral Palsy | 0.6 | 0.7 | -0.17 |
| Chronic Fatigue Syndrome | 1.7 | 1.4 | 0.21 |
| Chronic Kidney Disease | 1 | 0.6 | 0.67 |
| Chronic Lyme | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.4 | 0.6 | -0.5 |
| Chronic Urticaria (Hives) | 0.7 | 0.1 | 6 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 0.4 | 0.75 |
| Cognitive Function | 1 | 0.3 | 2.33 |
| Colorectal Cancer | 2.4 | 0.7 | 2.43 |
| Constipation | 1.5 | 0.1 | 14 |
| Coronary artery disease | 1 | 0.7 | 0.43 |
| COVID-19 | 2.3 | 2.8 | -0.22 |
| Crohn's Disease | 2.1 | 2.2 | -0.05 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.7 | 0.7 | 0 |
| d-lactic acidosis (one form of brain fog) | 0.1 | 0.1 | |
| deep vein thrombosis | 1 | 0.6 | 0.67 |
| Depression | 3.3 | 3.3 | 0 |
| Dermatomyositis | 0.3 | -0.3 | |
| Eczema | 0.6 | 0.3 | 1 |
| Endometriosis | 1.7 | 1 | 0.7 |
| Epilepsy | 1.5 | 0.9 | 0.67 |
| erectile dysfunction | 0.9 | 0.3 | 2 |
| Fibromyalgia | 0.4 | 0.7 | -0.75 |
| Functional constipation / chronic idiopathic constipation | 2.5 | 1.5 | 0.67 |
| gallstone disease (gsd) | 1.1 | 0.3 | 2.67 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.4 | -0.4 | |
| Generalized anxiety disorder | 1.5 | 1.1 | 0.36 |
| Gout | 0.8 | 0.3 | 1.67 |
| Graves' disease | 0.9 | 1.3 | -0.44 |
| Gulf War Syndrome | 0.4 | 0.5 | -0.25 |
| Halitosis | 0.3 | 0.3 | |
| Hashimoto's thyroiditis | 1.1 | 0.9 | 0.22 |
| Heart Failure | 2 | 0.8 | 1.5 |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| High Histamine/low DAO | 0.1 | 0.6 | -5 |
| hypercholesterolemia (High Cholesterol) | 0.1 | 0.1 | 0 |
| hyperglycemia | 1.3 | 0.9 | 0.44 |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypersomnia | 0.1 | -0.1 | |
| hypertension (High Blood Pressure | 2.1 | 1.9 | 0.11 |
| Hypothyroidism | 0.1 | 0.7 | -6 |
| Hypoxia | 1.3 | 0.3 | 3.33 |
| IgA nephropathy (IgAN) | 0.6 | 0.8 | -0.33 |
| Inflammatory Bowel Disease | 1.5 | 2.7 | -0.8 |
| Insomnia | 0.7 | 1.2 | -0.71 |
| Intelligence | 0.7 | 0.7 | |
| Intracranial aneurysms | 0.7 | 0.3 | 1.33 |
| Irritable Bowel Syndrome | 2 | 1.8 | 0.11 |
| ischemic stroke | 1.3 | 0.9 | 0.44 |
| Liver Cirrhosis | 2.1 | 2 | 0.05 |
| Long COVID | 1.9 | 2.8 | -0.47 |
| Low bone mineral density | 0.6 | -0.6 | |
| Lung Cancer | 0.7 | 0.6 | 0.17 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.6 | 0.9 | -0.5 |
| ME/CFS with IBS | 0.8 | -0.8 | |
| ME/CFS without IBS | 0.6 | -0.6 | |
| Menopause | 0.3 | 0.1 | 2 |
| Metabolic Syndrome | 2.2 | 2 | 0.1 |
| Mood Disorders | 3.3 | 2.7 | 0.22 |
| multiple chemical sensitivity [MCS] | 0.1 | 0.1 | 0 |
| Multiple Sclerosis | 1.7 | 1.7 | 0 |
| Multiple system atrophy (MSA) | 0.2 | 0.7 | -2.5 |
| myasthenia gravis | 0.6 | 0.6 | |
| neuropathic pain | 1 | -1 | |
| Neuropathy (all types) | 0.2 | 0.6 | -2 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.1 | 0.1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.9 | 2.1 | -0.11 |
| NonCeliac Gluten Sensitivity | 0.8 | 0.6 | 0.33 |
| Obesity | 3.6 | 2.9 | 0.24 |
| obsessive-compulsive disorder | 2 | 1.1 | 0.82 |
| Osteoarthritis | 1 | 0.9 | 0.11 |
| Osteoporosis | 1.2 | 0.5 | 1.4 |
| Parkinson's Disease | 2.9 | 2.2 | 0.32 |
| Polycystic ovary syndrome | 2.5 | 1.5 | 0.67 |
| Postural orthostatic tachycardia syndrome | 0.6 | -0.6 | |
| Premenstrual dysphoric disorder | 0.4 | 0.4 | |
| Primary sclerosing cholangitis | 0.3 | 0.9 | -2 |
| Psoriasis | 0.9 | 0.7 | 0.29 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.9 | 1 | 1.9 |
| Rosacea | 0.6 | 0.6 | |
| Schizophrenia | 1.9 | 1.6 | 0.19 |
| scoliosis | 0.4 | 0.7 | -0.75 |
| Sjögren syndrome | 0.7 | 0.7 | 0 |
| Sleep Apnea | 1.3 | 1 | 0.3 |
| Slow gastric motility / Gastroparesis | 0.7 | 0.3 | 1.33 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.7 | 0.2 | 2.5 |
| Stress / posttraumatic stress disorder | 0.7 | 1 | -0.43 |
| Systemic Lupus Erythematosus | 1.3 | 1 | 0.3 |
| Tic Disorder | 0.3 | 0.3 | 0 |
| Tourette syndrome | 0.1 | 0.3 | -2 |
| Type 1 Diabetes | 1.9 | 1.7 | 0.12 |
| Type 2 Diabetes | 2.2 | 1.9 | 0.16 |
| Ulcerative colitis | 1.7 | 1.5 | 0.13 |
| Unhealthy Ageing | 0.6 | 0.6 | 0 |
| Vitiligo | 1.2 | 0.5 | 1.4 |
